Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mareike Verbeek

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Blood Advances|August 19, 2024
Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantationTheresa Landspersky, Merle Stein, Mehmet Saçma, et al.
Molecular Cell|February 11, 2021
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myelomaMichael Heider, Ruth Eichner, Jacob Stroh, et al.
Journal of Translational Medicine|June 13, 2024
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2018
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR ReportFiroozeh Sahebi, Laurent Garderet, Abraham S Kanate, et al.
Bone Marrow Transplantation|May 27, 2026
Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMTAnnalisa Paviglianiti, Maud Ngoya, Regis Peffault de la Tour, et al.
Bone Marrow Transplantation|July 7, 2023
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)Eleni Gavriilaki, Ioanna Sakellari, Myriam Labopin, et al.
Bone Marrow Transplantation|March 13, 2025
Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysisOsama Ahmad, Nicolaus Kröger, Eva Wagner-Drouet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 3, 2018
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry AnalysisMarie Robin, Raphaël Porcher, Annalisa Ruggeri, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Blood Advances|August 19, 2024
Targeting CDC42 reduces skeletal degeneration after hematopoietic stem cell transplantationTheresa Landspersky, Merle Stein, Mehmet Saçma, et al.
Molecular Cell|February 11, 2021
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myelomaMichael Heider, Ruth Eichner, Jacob Stroh, et al.
Journal of Translational Medicine|June 13, 2024
Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Journal of Translational Medicine|November 22, 2023
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host diseaseHalvard Bonig, Mareike Verbeek, Peter Herhaus, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2018
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR ReportFiroozeh Sahebi, Laurent Garderet, Abraham S Kanate, et al.
Bone Marrow Transplantation|May 27, 2026
Outcomes of mixed phenotype acute leukemia undergoing allogeneic stem cell transplantation: a retrospective study of the ALWP of EBMTAnnalisa Paviglianiti, Maud Ngoya, Regis Peffault de la Tour, et al.
Bone Marrow Transplantation|July 7, 2023
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)Eleni Gavriilaki, Ioanna Sakellari, Myriam Labopin, et al.
Bone Marrow Transplantation|March 13, 2025
Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysisOsama Ahmad, Nicolaus Kröger, Eva Wagner-Drouet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 3, 2018
HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry AnalysisMarie Robin, Raphaël Porcher, Annalisa Ruggeri, et al.
Bone Marrow Transplantation|October 15, 2025
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMTPatryk Sobieralski, Tomasz Czerw, Luuk Gras, et al.
Pageof 7